This action increases insulin secretion, decreases glucagon release, and reduces appetite, mirroring the metabolic and weight control effects documented in injectable semaglutide studies such as SUSTAIN and STEP (Wilding et al., NEJM, 2021)
Cerebrolysins trial base is heavily Russian, Chinese, and Eastern European, several studies were manufacturer-supported, and that concentration is exactly the kind of thing that inflates apparent benefit
Not everyone wants rapid weight reduction
1 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2 Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy, 3 Department of Developmental Neuroscience, IRCCS, Stella Maris Foundation, Pisa, Italy, 4 Interdisciplinary Research Center Health Science, SantAnna School of Advanced Studies, Pisa, Italy